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Familial amyloid polyneuropathy (FAP) is a genetic, adult-onset, neurodegenerative disorder caused by
amyloid formation of transthyretin (TTR), a thyroxine-binding protein. Mutation in TTR causes a pro-
pensity of TTR tetramer to dissociate to monomer, which is the ﬁrst step to amyloidosis. Thus, a drug that
can stabilize the tetramer structure will have therapeutic beneﬁt. Here, by virtual screening and
biochemical assays, we identiﬁed small molecule 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-
1,3(2H)-dione (L6) that can prevent the dissociation of TTR to monomer. X-ray crystallography reveals
that L6 binds to the T4 binding pocket of TTR. These ﬁndings show that L6 is a candidate TTR stabilizer.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Main body
Transthyretin is a tetrameric b-strand protein found in serum
and cerebrospinal ﬂuid and is involved in the transport of thyroxine
(T4) hormone and retinol binding protein reviewed in (1). TTR
forms a 55-kDa homotetramer composed of four identical mono-
mers with 127 amino acid residues. Mutation in TTR, commonly
V30M TTR, destabilizes the tetramer form of this protein. The
dissociation of the TTR tetramer into monomer is the rate-limiting
step for amyloid ﬁbril formation, leading to amyloid ﬁbril deposi-
tion in various organs and multiple organ failure (1). The patho-
logical conditions induced by TTR mutation include FAP, familial
amyloidotic cardiomyopathy and central nervous system amyloid-
osis. Current treatment approach for FAP is limited to liver trans-
plantation. Recently, the clinical effects of TTR tetramer stabilizers,u, Kumamoto City 862-0973,
a City 930-0194, Japan.
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. Production and hosting by Elsesuch as tafamidis and diﬂunisal, are extensively explored (2). These
drugs function by binding one or both of the equivalent T4 sites at
the TTR quaternary structure interface. However, these drugs
especially the NSAIDs are restricted by the class of TTR variants.
Variants possessing a mutation around the T4 binding pocket are
resistant to the effects of diﬂunisal, diclofenac and niﬂumic acid (3).
Diﬂunisal was previously reported to bind to the T4 binding sites of
wild-type TTR (Kd1 ¼ 75 nM, Kd2 ¼ 1.1 mM) and inhibit TTR disso-
ciation. The mode of its binding to TTR has been described (4). But
the efﬁcacy of inhibition by diﬂunisal is diminished proportional to
the instability of the tetrameric TTR variant. Because the most
common variant, V30M TTR, is unstable, diﬂunisal lost signiﬁcant
activity against V30M TTR (5). In addition, diﬂunisal is not a speciﬁc
ligand for TTR in the serum, as it also binds to albumin. From the
clinical perspective, diﬂunisal showed adverse effects in some pa-
tients such as deterioration of renal function and thrombocyto-
penia (6), and being an NSAID, long-term administration could lead
to gastrointestinal side effects. Therefore, it is important to
continue searching for other small molecules that have potential as
tetramer stabilizers.
Originally, by virtual screening, we were searching for a com-
pound that binds to the monomeremonomer interface of TTR and
disturbs the formation of the TTR tetramer. For virtual screening,
the monomer structure of WT TTR, which was extracted from TTRvier B.V. This is an open access article under the CC BY-NC-ND license (http://
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used as a receptor, and Lead-like virtual chemical library was ob-
tained from the ZINC website conducted by University of California,
San Francisco (8). The docking calculations were carried out using
AutoDock Vina (9). Consequently, we obtained 9 candidate com-
pounds (L1eL9) from the virtual screening of 2 million molecules
(Supplemental Table S1, S2 and Supplemental Fig. S1). However, in
the biochemical assays, we found that one candidate compound, 6-
benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione (L6),
bound to the T4 binding sites but not to the monomeremonomer
interface and stabilized the TTR tetramer.
Initially, we examined the effects of L compounds by incubating
HEK293 cells stably expressing V30M TTR with 10 mM of L1 to L9
compounds. The HEK293 V30M TTR stable cells were generated by
transfecting V30M TTR plasmid followed by blasticidin (10 mg/ml)
selection. These cells were cultured at 37 C incubator in DMEM
with 10% fetal bovine serum and 2% antibiotics. By western blotting
analysis of cell media, we detected TTR dimer from cells treated
with L6 compound (Fig. 1A). This result suggests that among the L
compounds, L6 is a possible stabilizer of secreted TTR. L6 has aFig. 1. Effect of compound L6 on the stabilization of TTR tetramer. (A) HEK293 cells stably ex
Culture media were collected and analyzed by Western blotting using anti-TTR antibody (fro
hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione (L6). (CeD) Recombinant WT TTR (C) or V
TTR; pH 4.4 for V30M TTR) with the indicated concentration of L6 or Diﬂunisal or both. Ag
staining (Fig. 1D, upper panel). Graphs shown are representative of 3 independent experim
ANOVA with Dunnett test or TukeyeKramer test. (E) Summary of the Kd, IC50 and Ki. (F) Sem
Semilog plot of the inhibition ratio at various concentration of (G) L6 or (H) diﬂunisal in thnovel skeletal structure (Fig. 1B) among the known TTR stabilizers.
Thus, we determined the inhibitory activity of L6 against amyloid
ﬁbril formation of TTR by ThT assay. Recombinant wild-type (WT)
and V30M TTRs (0.2 mg/ml), generated previously (3, 10), were
incubated with 200 mM acetate buffer in 100 mM KCl, 1 mM EDTA
and the indicated concentration of L6 and/or diﬂunisal for 72 h (pH
3.8 or 4.4), in a process termed “aging”. Amyloid ﬁbril formation
was determined by ThT assay using the procedure reported previ-
ously (3, 10). Fluorescence emission spectra were obtained with
excitation and wavelengths of 450 and 482 nm, respectively.
Fluorescence measurements were performed using FP-777 Jasco
spectroﬂuorometer. L6 at 10 and 30 mM suppressed the formation
of amyloid ﬁbrils as determined by ThT assay (Fig. 1C, upper panel).
Consistent with previous studies (4), diﬂunisal also suppressed
amyloid formation of WT TTR. The combination of L6 and diﬂunisal
strongly suppressed amyloid formation of WT TTR (Fig. 1C, lower
panel).
Because V30M TTR is the most common variant in FAP patients,
we closely examined the effect of L6 on this TTR variant. Aging
samples of V30M were analyzed by Coomassie Brilliant Blue (CBB)pressing V30M TTR were incubated with 10 mM of the indicated L compounds for 24 h.
m Dako). “#” indicates non-speciﬁc bands. (B) The chemical structure of 6-benzoyl-2-
30M TTR (D) was incubated for 72 h at 37 C in 200 mM acetate buffer (pH 3.8 for WT
ing samples were analyzed by ThT binding assay (Fig. 1C, D, lower panel) and by CBB
ents. Values represent the mean ± S.D. *, P < 0.05, **, P < 0.01, vs control, assessed by
ilog plot of the ﬂuorescence intensity of ANS in the presence of 1 mM WT TTR. (GeH)
e presence of 1 mM WT TTR and 20 mM ANS.
Table 1
Statistics on X-ray data and structure reﬁnement.
WT-TTR-L6
Crystal data
Resolution rangea (Å) 36.35  1.4 (1.43  1.40)
Space group P21212
Unit cell (Å) a ¼ 43.6, b ¼ 84.8, c ¼ 65.3
Observed reﬂections 206,217
Unique reﬂectionsa 46,782 (2,172)
Rmerge
ab , Rpimc (%) 5.7 (46.3), 2.7 (29.2)
Completenessa (%) 96.2 (90.4)
I/sigma(I)a 27.4 (1.6)
Redundancya 4.4 (3)
Reﬁnement data
Rfactor
d (%), Rfreee (%) 18.9, 20.9
R.M.S.D. bonds (Å) 0.014
R.M.S.D. angles () 1.7
No. of water 244
Average B factor (Å2)
protein, ligand, water 18.8, 24.1, 32.4
Ramachandran plot (%)
Favored, allowed 97.4, 2.6
Fig. 2. Crystal structure of WT TTR in complex with L6. (A). Overall crystal structure of TTR w
(B) Omit difference Fourier map around L6 contoured at 2.8 s. (C) Interactions between W
silver, respectively. The oxygen and nitrogen atoms are colored red and blue, respectively. H
molecule is represented as sphere model.
T. Yokoyama et al. / Journal of Pharmacological Sciences 129 (2015) 240e243242staining after SDS-PAGE on 14% gel. V30M TTR monomer formation
was inhibited by L6 at 10 mM but not at 3.6 mM (Fig. 1D, upper
panel). Interestingly, the combination of L6 and diﬂunisal at 10 mM
and 3.6 mM, respectively, remarkably suppressed V30M TTR
monomer and amyloid ﬁbril formation, accompanied with a sta-
bilization of V30M TTR tetramer (Fig. 1D). Taken together, these
results suggest that L6, especially in combination with low con-
centration diﬂunisal, has the potential to inhibit dissociation of TTR
tetramer.
Next, we assessed the direct binding of L6 to TTR by ﬂuorometric
assay using competitive binding with 1-Anilinonaphthalene-8-
Sulfonic Acid (ANS), which is known to bind to the T4 binding
site of TTR as previously reported (11). Fluorescence intensities
were measured in a 96-well microplate (Thermo Fisher Scientiﬁc)
by a microplate reader (GENios; Tecan Group Ltd.) with the exci-
tation and emission wavelengths of 360 and 465 nm, respectively.
For the Kd determination of ANS, the ﬂuorescence intensities at
various concentrations of ANS (0e100 mM) were measured in the
presence of 1 mM WT-TTR or V30M TTR (50 mM TriseHCl [pH 7.5]ith L6 binding at the T4 binding pocket. L6 molecules are represented as sphere model.
T-TTR and L6. The carbon atoms of subunits A, C and L6 are colored green, yellow and
ydrogen bonds and CH/p interactions are indicated as yellow dashed lines. The water
T. Yokoyama et al. / Journal of Pharmacological Sciences 129 (2015) 240e243 243and 150 mM NaCl). Similarly, for the IC50 determination of L6 and
diﬂunisal, the ﬂuorescence intensities at various concentrations of
ligands (0e100 mM)were measured in the presence of 1 mMprotein
and 20 mMANS. The binding and inhibitory curves were ﬁtted using
the 4-parameter logistic model by the least squares methods (12).
The Kd and IC50 values and standard deviations were calculated
fromduplicate experiments. The Ki values (dissociation constant for
the inhibitor) were calculated using the equation: Ki ¼ IC50/(1 þ LT/
Kd), where LT is the total concentration of ANS (13). The ﬂuores-
cence intensities of ANS in the presence of 1 mMTTRwere increased
in a dose-dependent manner, and the Kd values for WT TTR and
V30M TTR were 3.2 and 3.3 mM, respectively (Fig. 1E, F). Notably, L6
dose-dependently increased the inhibition ratio in the presence of
1 mMTTR and 20 mMANS, indicating that L6 competitively bound to
the T4 binding sites of TTR with ANS (Fig. 1G). The IC50 values for
WT TTR and V30M TTR against the binding of ANS were 1.3 and
1.6 mM, respectively. Diﬂunisal, as expected, was also able to
compete against ANS for binding with TTR (Fig. 1H). In addition,
here we assessed the binding of ANS and L6 to amyloidogenic L55P
and Y116S mutant TTR. While the binding afﬁnities of ANS were
similar among tested TTR variants, the Ki values of L6 and diﬂunisal
against L55P were rather high compared to those against WT and
V30M (Fig. 1E).
The binding of L6 to TTR was further veriﬁed by X-ray crystal-
lography. WT TTR-L6 complex crystals were grown by mixing 2 mL
of protein solution [19 mg/mL protein, 1 mM L6, 20 mM TriseHCl
pH 8.0 and 150 mM NaCl] with 2 L of reservoir solution [18%
polyethylene glycol 400, 0.1 M HEPES pH 7.0 and 0.2 M CaCl2] using
the hanging-drop vapor diffusion method at 293 K. X-ray diffrac-
tion data was collected at beamline NW12A at the Photon Factory
Advanced Ring in Japan. The diffraction data sets were processed
with HKL2000 and SCALEPACK. The X-ray structure of WT-TTR in
apo form at cryo temperature (PDB code: 4N85) (14) was used as
the initial model. The 3D structures and the dictionary data (cif) of
L6 were obtained using the PRODRG server. The protein structures
were reﬁned using PHENIX.REFINE with stepwise cycles of manual
model building using COOT (15). Crystal and reﬁnement data are
summarized in Table 1. The coordinates and structure factors of
WT-TTR-L6 and have been deposited at the Protein Data Bank un-
der the accession code 5AYT.
X-ray crystallographic analysis of WT-TTR in complex with L6 at
1.4 Å resolution revealed that L6 bound to the T4 binding sites
(Fig. 2AeB) consistent with the data in ANS competitive assay. A
water molecule was found between L6 and TTR, and a hydrogen-
bond network was formed among S117, T119 and the carbonyl
group of L6 (Fig. 2C). The side chains of L17 and A108 were
3.0e3.7 Å distant from the center of the benzene ring moiety of L6,
indicating that there were CH/p interactions. The hydrogen bonds
were found between the side chains of K15 and the hydroxyl group
of L6. The binding of L6 would be stabilized by these interactions.
Overall, these ﬁndings reveal that L6 binds to TTR at the T4 binding
pocket and is a novel TTR tetramer stabilizer.Conﬂict of interest
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